

TANDEM DIABETES CARE INC  
Form SC 13G/A  
February 13, 2019

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**(Amendment No. 1)\***

**Under the Securities Exchange Act of 1934**

**Tandem Diabetes Care, Inc.**

**(Name of Issuer)**

**Common Stock, par value \$0.001 per share**

**(Title of Class of Securities)**

**875372 104**

**(CUSIP Number)**

**December 31, 2018**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**SCHEDULE 13G**

**CUSIP No. 875372 104**

**Page 2 of 4 Pages**

**1** NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)

DexCom, Inc.

**2** CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) (b)

**3** SEC USE ONLY

**4** CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware, U.S.A.

**5** SOLE VOTING POWER

**NUMBER OF**

**SHARES** 1,000,000  
**6** SHARED VOTING POWER

**BENEFICIALLY**

**OWNED BY** 0  
**EACH** **7** SOLE DISPOSITIVE POWER

**REPORTING**

**PERSON** 1,000,000  
**8** SHARED DISPOSITIVE POWER

**WITH**

0

**9** AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,000,000

**10** CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

**11** PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

1.74%

**12** TYPE OF REPORTING PERSON (See Instructions)

CO

**SCHEDULE 13G**

**CUSIP No. 875372 104**

**Page 3 of 4 Pages**

**Item 1.**

(a) Name of Issuer:  
Tandem Diabetes Care, Inc.

(b) Address of Issuer's Principal Executive Offices:  
11045 Roselle Street  
  
San Diego, CA 92121

**Item 2.**

(a) Name of Person Filing:  
DexCom, Inc.

(b) Address of Principal Business Office:  
6340 Sequence Drive  
  
San Diego, CA 92121

(c) Citizenship:  
Delaware, U.S.A.

(d) Title of Class of Securities:  
Common Stock

(e) CUSIP Number:

875372 104

**Item 3. Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):**  
Not applicable.

**Item 4. Ownership.**

(a) Amount beneficially owned:  
1,000,000

(b) Percent of class:  
1.74%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

1,000,000

(ii) Shared power to vote or to direct the vote:

0

(iii) Sole power to dispose or to direct the disposition of:

1,000,000

(iv) Shared power to dispose or to direct the disposition of:

0

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

**Item 6. Ownership of More Than Five Percent on Behalf of Another Person.**

Not Applicable.

**Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person**

Not applicable.

**Item 8. Identification and Classification of Members of the Group**

Not applicable.

**Item 9. Notice of Dissolution of Group**

Not applicable.

**Item 10. Certifications**

Not applicable.



**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**DEXCOM, INC.**

Dated: February 13, 2019

By: /s/ Quentin Blackford  
Name: Quentin Blackford  
Title: Chief Financial Officer